MyFinsight
Home
Blog
About
Contact
Proceeds from
at-the-market offering, net of...
$85,371K
Proceeds from exercise of
common stock options
$2,442K
Net cash provided by
financing activities
$87,435K
Canceled cashflow
$378K
Net decrease in cash
and cash...
-$29,870K
Canceled cashflow
$87,435K
Maturities of marketable
securities
$57,500K
Stock-based compensation
expense
$5,484K
Accounts payable
$3,972K
Depreciation expense
$64K
Non cash operating
lease expense
$34K
Payments related to
offering costs
$378K
Net cash (used in)
provided by investing...
-$97,097K
Canceled cashflow
$57,500K
Net cash used in
operating activities
-$20,208K
Canceled cashflow
$9,554K
Purchases of marketable
securities
$154,160K
Purchases of property and
equipment
$437K
Net loss
-$23,517K
Accrued expenses
-$4,857K
Prepaid expenses and
other current assets
$725K
Accretion and
amortization of marketable...
$579K
Other assets
$43K
Operating lease liability
-$41K
Back
Back
Cash Flow
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)
source: myfinsight.com